Risk Factor Modification: The Evidence Base for Primary Prevention

Definition and Scope

Primary prevention aims to prevent the clinical manifestation of cardiovascular disease (CVD) in individuals without established clinical CVD. It differs from primordial prevention, which seeks to prevent the development of cardiovascular risk factors themselves, and from secondary prevention, which addresses patients with established disease to reduce recurrent events and mortality.

Risk-factor modification is therefore directed at identifying individuals at increased risk and reducing exposure to established, modifiable determinants of cardiovascular disease. The principal targets include blood pressure, lipid abnormalities, diabetes and glycaemic status, body weight, smoking, diet, physical inactivity, and alcohol consumption. Additional considerations include psychosocial stress, obstructive sleep apnoea, social determinants of health, air pollution, family history, ethnicity, and frailty.

Primary prevention is complemented by population-level interventions. Population strategies aim to shift risk across the whole community through healthier environmental defaults, whereas individual-level prevention focuses more intensively on people with elevated risk. These approaches are not alternatives: both are required to reduce the overall cardiovascular burden.

Pathophysiological and Epidemiological Basis

The lifetime burden of CVD is related to the number and severity of cardiovascular risk factors. Five modifiable factors—systolic blood pressure, non-HDL cholesterol, diabetes, body mass index, and current smoking—account for more than half of the population-attributable risk of cardiovascular mortality and approximately one-fifth of the risk of all-cause mortality in the cited international cohort evidence.

Metabolic risk factors make a particularly large contribution to cardiovascular disease. Hypertension is a major component of this burden, followed by non-HDL cholesterol. For myocardial infarction, the leading contributors include high non-HDL cholesterol, hypertension, smoking, abdominal obesity, and diabetes. Behavioural factors also make a substantial contribution to all-cause mortality, while low educational attainment contributes materially to overall risk.

The population impact of a risk factor depends not only on the relative risk associated with exposure but also on how common the exposure is. Consequently, a modest reduction in risk across a large population may prevent more events than a major reduction in risk among a small number of high-risk individuals. This principle underlies the population approach to cardiovascular prevention.

Cardiovascular Prevention Across the Life Course

Primordial prevention

Primordial prevention seeks to prevent the emergence of risk factors. It includes maintenance of favourable blood pressure, body mass index, cholesterol and glucose levels, together with a low-salt, low-cholesterol diet, regular physical activity, avoidance of smoking, and adequate sleep.

The process should begin early in life. Primordial prevention in childhood may reduce the subsequent development of hypertension, elevated LDL cholesterol, obesity and smoking. Its purpose is to limit both the intensity and duration of exposure to cardiovascular risk factors.

Primary prevention

Primary prevention targets people without clinical CVD who nevertheless have established risk factors or an elevated estimated risk. It combines lifestyle intervention with treatment of risk factors when indicated. Risk estimation is particularly important when deciding which individuals are most likely to benefit from preventive drug therapy.

Secondary prevention

Although outside the principal scope of primary prevention, secondary prevention provides an important contrast. Patients with manifest clinical disease are at high risk of progression and generally require all appropriate evidence-based measures, including drug treatment and therapeutic lifestyle change. Implementation remains suboptimal: approximately half of patients may still be taking recommended secondary-prevention medication, such as statins, one year after myocardial infarction.

Assessment of Cardiovascular Risk

Conventional risk assessment

Risk scores are used to identify individuals who may benefit from targeted behavioural or pharmacological intervention. Common variables include:

• Age

• Sex

• Blood pressure or hypertension status

• Smoking status

• Diabetes mellitus

• Lipid values

• Family history in some models

Absolute risk estimation is central to primary prevention because it helps place a person's risk in the context of the foreseeable future or remaining lifespan. However, risk scores derived in one population may not perform equally well in another, and risk may be under- or overestimated in different ethnic groups.

Where laboratory testing is limited, non-laboratory prediction tools may be useful. A tool based on age, systolic blood pressure, body mass index, diabetes status and smoking status predicted cardiovascular outcomes comparably to a laboratory-based Framingham-derived tool in the cited analysis. The WHO has also developed regional risk-prediction charts with and without cholesterol information.

Risk assessment in resource-limited settings

In settings where laboratory testing is expensive or unavailable, simplified risk tools can facilitate screening. Community health workers may use such scores to reduce the cost of case finding. Prediction rules that require laboratory results may be impractical for widespread use in low- and middle-income countries.

The ankle–brachial index

The ankle–brachial index may improve risk discrimination and reclassification and is an alternative non-invasive measure of vascular risk. The American Heart Association and American College of Cardiology recommend ABI assessment among high-risk individuals. The US Preventive Services Task Force has noted limited information regarding whether ABI use improves treatment decisions in the general asymptomatic population.

Risk modifiers

Additional information may be considered when it is likely to improve risk prediction or reclassification, is feasible in routine practice, has a clear public-health benefit, and can influence management in both directions. Risk modifiers are most useful when an individual's estimated risk is close to a treatment decision threshold. In individuals at very low or very high risk, additional testing is less likely to change management.

The magnitude by which a risk modifier changes calculated absolute risk is generally smaller than the independent relative risks reported in observational literature. A favourable modifier profile should reduce risk estimates as well as an unfavourable profile increasing them.

Relevant modifiers include:

• Family history of premature atherosclerotic cardiovascular disease

• Psychosocial stress

• Ethnic background

• Frailty

• Obesity

• Social circumstances and deprivation

• Air pollution

• Coronary artery calcium (CAC) score

CAC scoring is the best-established imaging modality for improving cardiovascular risk stratification. It may be particularly useful in intermediate-risk populations and has been reported to be cost-effective in high-income settings.

Genomic risk scores are not currently supported for routine cardiovascular risk assessment in primary prevention. Additional circulating and urinary biomarkers should not be measured routinely.

Frailty is a functional risk factor for both cardiovascular and non-cardiovascular morbidity and mortality. It should be used to develop an individualized care plan with explicit priorities rather than to determine eligibility for a particular treatment.

Clinical Evaluation and Preventive Consultation

Primary prevention requires more than calculation of a numerical risk estimate. The clinical assessment should establish the patient's understanding of risk, readiness to change, preferences regarding medication, and capacity to implement the proposed regimen.

Important domains include:

• Dietary pattern and sodium intake

• Body weight and weight trajectory

• Physical activity and sedentary behaviour

• Tobacco and alcohol use

• Blood pressure history and treatment

• Diabetes or abnormal glucose regulation

• Lipid abnormalities

• Sleep and possible obstructive sleep apnoea

• Psychosocial stress

• Family history of premature ASCVD

• Social circumstances, health literacy, cost and practical barriers

• Functional status and frailty

Counselling should be collaborative. Motivational interviewing may help identify an intervention that the patient is prepared to undertake. Selecting an initial goal that aligns with the patient's readiness may improve both short- and long-term adherence.

When several risks are present, priorities should be discussed explicitly. If immediate risk reduction is the principal objective, blood pressure control and smoking cessation may produce more rapid reductions in acute cardiovascular risk than some other lifestyle interventions. This does not diminish the importance of lipid management, weight optimization, diet or physical activity; rather, it helps organize treatment when capacity and resources are limited.

Lifestyle-Based Risk-Factor Modification

Diet

Dietary interventions should support healthy body weight, improve metabolic markers and reduce blood pressure. Reduction of sodium intake is specifically associated with improved metabolic and blood-pressure measures. A Mediterranean dietary pattern was associated with a lower risk of incident peripheral arterial disease than the comparator diet in a secondary analysis of a randomized trial.

Population-level dietary policies may include reduction of salt, sugar, alcohol and trans-fat consumption, together with improved access to healthy foods. Dietary change often requires sustained support because benefits may develop gradually, although they can persist over the long term and improve health-related quality of life and well-being.

Weight optimization

Maintaining an optimal body mass index and addressing obesity are central to primordial and primary prevention. Patients with obesity should undergo cardiovascular risk assessment. Weight optimization may also improve metabolic markers and blood pressure.

Excess weight is a priority because of its multiple associated complications. Intervention should be integrated with dietary counselling, physical activity and management of accompanying hypertension, diabetes and dyslipidaemia.

Physical activity and sedentary behaviour

Regular physical activity is a component of optimal cardiovascular health. Sedentary behaviour is a social and behavioural determinant of cardiovascular risk. Counselling regarding physical activity has become a routine component of preventive care, although sustained behaviour change may be difficult.

At the population level, urban design, transport, workplace environments and community programmes can either facilitate or discourage physical activity. Broad interventions may produce modest benefits for each individual but substantial reductions in population disease burden.

Smoking and tobacco use

Smoking cessation is among the most important preventive interventions. Assistance from healthcare professionals is strongly supported as a means of changing health behaviour. Tobacco control also requires educational campaigns, community interventions and public policies.

Smoking cessation may reduce the risk of acute cardiovascular events more rapidly than some other lifestyle interventions and should therefore be prioritized when smoking is present.

Alcohol

Alcohol consumption is a modifiable population and individual risk factor. The source material supports its inclusion in cardiovascular risk modification and population strategies, including efforts to reduce consumption, but does not provide specific intake thresholds or pharmacological treatment regimens.

Sleep and obstructive sleep apnoea

Restful sleep is included among the components of optimal cardiovascular health. Obstructive sleep apnoea is identified as a modifiable condition relevant to cardiovascular and atrial fibrillation prevention. Specific diagnostic pathways or treatment regimens are not detailed in the source material.

Psychosocial and social determinants

Psychosocial stress is associated with atherosclerotic cardiovascular disease risk and may improve risk prediction beyond classical models. Cardiovascular risk is also linked to social gradients, including education, occupation, income, wealth inequality, neighbourhood design and social networks.

Primordial prevention therefore extends beyond individual behaviour. Broader measures include improving daily living conditions, reducing poverty and illiteracy, strengthening healthcare access and financing, and addressing determinants related to agriculture, transportation and employment.

Management of Established Modifiable Risk Factors

Blood pressure

Hypertension is a major modifiable determinant of cardiovascular risk and a prominent contributor to myocardial infarction and overall CVD burden. Blood pressure control is therefore a central component of primary prevention.

In patients with multiple untreated risk factors, blood-pressure management may be selected as the initial priority because blood pressure is both a chronic risk factor and an acute trigger for cardiovascular events. The source material does not specify blood-pressure thresholds, treatment targets, drug classes, or doses.

Lipids

Non-HDL cholesterol is a major contributor to cardiovascular risk and is the leading cited risk factor for myocardial infarction. Screening and treatment of elevated cholesterol are identified as important, low-cost preventive interventions.

The source material does not provide lipid thresholds, treatment targets, statin intensity, non-statin treatment indications, or drug doses.

Diabetes and glucose control

Diabetes is a major modifiable cardiovascular risk factor. Glucose management is particularly important for preventing microvascular complications, including neuropathy and amputation, in patients with peripheral arterial disease.

The WHO Best Buys programme recommends drug therapy for diabetes mellitus using an absolute-risk approach. Specific glucose targets and antidiabetic drug regimens are not provided.

Peripheral arterial disease

Intensive risk-factor management is critical in patients with peripheral arterial disease because of their increased cardiovascular risk. Management includes dietary improvement, weight optimization, exercise, smoking cessation and optimization of hypertension, diabetes and dyslipidaemia. In this setting, glucose management also has implications for neuropathy and amputation prevention.

Pharmacological Prevention

Primary prevention may include pharmacological treatment of established risk factors when the expected absolute benefit justifies treatment. Decisions should incorporate estimated risk, potential benefits and harms, patient preferences, health literacy, cost and capacity to adhere.

The WHO Best Buys programme supports drug therapy for diabetes and hypertension control using an absolute-risk approach. The cited material also describes a “polypill” strategy comprising aspirin, a statin and an antihypertensive agent; trial data have demonstrated reductions in events in both primary and secondary prevention, and this regimen has been included on the WHO Essential Medicines list.

No specific drug doses, treatment thresholds, monitoring schedules or contraindications are provided. Aspirin should therefore not be prescribed in primary prevention on the basis of the supplied material alone without an individualized assessment of benefit and harm.

Guideline-Based Principles

The guideline-based principles supported by the source material are summarized below.

Implementation and Adherence

Preventive care commonly involves multiple simultaneous interventions. Barriers include medication cost, time, health literacy, patient and caregiver capacity, and the complexity of treatment regimens. These barriers should be addressed explicitly because failure to do so may lead to therapeutic failure.

Treatment plans should be coordinated, intensive where appropriate, and combine behavioural and pharmacological management. In people with severe mental illness, the same fundamental risk-factor principles apply as in the general population, but improved effectiveness is associated with a multimorbidity approach, high intensity and strong coordination, together with behavioural counselling and peer or family support.

Preventive decisions may require more than one conversation. The clinician should explain absolute risk, expected benefits, possible harms and the uncertainty surrounding some interventions. Patient preferences should remain central, particularly when the anticipated benefit is modest or treatment decisions are close to a threshold.

Population-Level Prevention

Population prevention addresses the social and environmental context in which individual choices occur. Measures include:

• Tobacco-control policies

• Reduction of trans fats

• Lower population salt, sugar and alcohol intake

• Promotion of healthy dietary patterns

• Environments that facilitate physical activity

• Better urban and transport planning

• Improvements in education, employment and living conditions

• Reduction of poverty and social deprivation

• Improved health literacy and healthcare access

These interventions may take time, require substantial investment and produce benefits slowly. Their effects can nevertheless persist over the long term and may improve quality of life, reduce health inequalities and prevent other conditions, including cancer, pulmonary disease and type 2 diabetes.

Population strategies and high-risk strategies should coexist. Population interventions reduce the overall exposure burden, while targeted screening and treatment provide greater benefit to individuals whose risk is sufficiently high.

Prognosis and Follow-Up

The objective of primary prevention is to reduce lifetime cardiovascular risk and prevent first clinical events. The greatest potential benefit is achieved when risk-factor exposure is reduced early and maintained over time.

Follow-up should reassess:

• Blood pressure and its control

• Weight and dietary progress

• Smoking and alcohol status

• Physical activity

• Diabetes and glucose management

• Lipid abnormalities

• Medication adherence and tolerability

• New comorbidities or evidence of vascular disease

• Frailty and functional status

• Patient understanding, preferences and readiness for further change

The interval and specific investigations should be individualized according to baseline risk, treatment intensity, comorbidity and the feasibility of sustained intervention. Where risk estimates remain close to a decision threshold, selected risk modifiers may be reconsidered, although additional testing should not be pursued routinely when it is unlikely to alter management.

Successful prevention depends on long-term continuity rather than a single risk calculation or brief intervention. Persistent attention to modifiable risk factors, patient priorities and structural barriers is required to translate preventive recommendations into durable reductions in cardiovascular disease.